SYNLOGIC, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SYNLOGIC, INC. (SYBX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.20 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-11-12
- SYNLOGIC, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.20, a 556.25% increase year-over-year.
- SYNLOGIC, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.64, a 67.84% decline year-over-year.
- SYNLOGIC, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.99, a 42.98% decline year-over-year.
- SYNLOGIC, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $3.49.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2024-09-30 | $4.20 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $4.20 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $4.20 10-Q · filed 2024-05-14 | ||
| 2023-09-30 | $9.31 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $0.63 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $0.64 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | $1.70 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $1.84 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $1.99 10-Q · filed 2022-05-12 | ||
| 2021-09-30 | $3.46 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $3.52 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $3.49 10-Q · filed 2021-05-13 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | ||
| 2016-09-30 | $4.41 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $4.40 10-Q · filed 2016-08-15 | ||
| 2016-03-31 | $4.37 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |